Cancer biotech Loxo Oncology files for a $69 million IPO

By Renaissance Capital,

Shutterstock photo

Loxo Oncology, which is developing small molecule therapeutics for the treatment of solid tumors, filed on Monday with the SEC to raise up to $69 million in an initial public offering. The Stamford, CT-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol LOXO. Loxo Oncology initially filed confidentially on May 14, 2014. Cowen & Company and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: LOXO

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by